These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 8980410)

  • 1. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
    Bokemeyer C; Fels LM; Dunn T; Voigt W; Gaedeke J; Schmoll HJ; Stolte H; Lentzen H
    Br J Cancer; 1996 Dec; 74(12):2036-41. PubMed ID: 8980410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin nephrotoxicity and protection by silibinin.
    Gaedeke J; Fels LM; Bokemeyer C; Mengs U; Stolte H; Lentzen H
    Nephrol Dial Transplant; 1996 Jan; 11(1):55-62. PubMed ID: 8649653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats.
    Humanes B; Lazaro A; Camano S; Moreno-Gordaliza E; Lazaro JA; Blanco-Codesido M; Lara JM; Ortiz A; Gomez-Gomez MM; Martín-Vasallo P; Tejedor A
    Kidney Int; 2012 Sep; 82(6):652-63. PubMed ID: 22718191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
    Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
    J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
    Hartmann JT; Knop S; Fels LM; van Vangerow A; Stolte H; Kanz L; Bokemeyer C
    Anticancer Drugs; 2000 Jan; 11(1):1-6. PubMed ID: 10757556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against cisplatin-induced nephrotoxicity by Spirulina in rats.
    Mohan IK; Khan M; Shobha JC; Naidu MU; Prayag A; Kuppusamy P; Kutala VK
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):802-8. PubMed ID: 16552571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide.
    Dietrich J; Marienhagen J; Schalke B; Bogdahn U; Schlachetzki F
    Ann Pharmacother; 2004 Feb; 38(2):242-6. PubMed ID: 14742759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway.
    Wainford RD; Weaver RJ; Stewart KN; Brown P; Hawksworth GM
    Toxicology; 2008 Jul; 249(2-3):184-93. PubMed ID: 18583013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
    Bokemeyer C; Schmoll HJ; Ludwig E; Harstrick A; Dunn T; Casper J
    Br J Cancer; 1994 May; 69(5):863-7. PubMed ID: 8180015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
    Koch Nogueira PC; Hadj-Aïssa A; Schell M; Dubourg L; Brunat-Mentigny M; Cochat P
    Pediatr Nephrol; 1998 Sep; 12(7):572-5. PubMed ID: 9761357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
    Beyer J; Rick O; Weinknecht S; Kingreen D; Lenz K; Siegert W
    Bone Marrow Transplant; 1997 Nov; 20(10):813-9. PubMed ID: 9404920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
    Klaassen U; Harstrick A; Schleucher N; Vanhoefer U; Schröder J; Wilke H; Seeber S
    Br J Cancer; 1996 Jul; 74(2):224-8. PubMed ID: 8688325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
    Arndt C; Morgenstern B; Hawkins D; Wilson D; Liedtke R; Miser J
    Med Pediatr Oncol; 1999 Feb; 32(2):93-6. PubMed ID: 9950195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children.
    Fujieda M; Matsunaga A; Hayashi A; Tauchi H; Chayama K; Sekine T
    J Toxicol Sci; 2009; 34 Suppl 2():SP251-7. PubMed ID: 19571477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of silibinin on experimental cyclosporine nephrotoxicity.
    Zima T; Kameníková L; Janebová M; Buchar E; Crkovská J; Tesar V
    Ren Fail; 1998 May; 20(3):471-9. PubMed ID: 9606735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
    Fields KK; Elfenbein GJ; Lazarus HM; Cooper BW; Perkins JB; Creger RJ; Ballester OF; Hiemenz JH; Janssen WE; Zorsky PE
    J Clin Oncol; 1995 Feb; 13(2):323-32. PubMed ID: 7844593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.